Matches in SemOpenAlex for { <https://semopenalex.org/work/W3037940748> ?p ?o ?g. }
- W3037940748 endingPage "4887" @default.
- W3037940748 startingPage "4871" @default.
- W3037940748 abstract "Mechanisms driving tumor progression from less aggressive subtypes to more aggressive states represent key targets for therapy. We identified a subset of luminal A primary breast tumors that give rise to HER2-enriched (HER2E) subtype metastases, but remain clinically HER2 negative (cHER2–). By testing the unique genetic and transcriptomic features of these cases, we developed the hypothesis that FGFR4 likely participates in this subtype switching. To evaluate this, we developed 2 FGFR4 genomic signatures using a patient-derived xenograft (PDX) model treated with an FGFR4 inhibitor, which inhibited PDX growth in vivo. Bulk tumor gene expression analysis and single-cell RNA sequencing demonstrated that the inhibition of FGFR4 signaling caused molecular switching. In the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) breast cancer cohort, FGFR4-induced and FGFR4-repressed signatures each predicted overall survival. Additionally, the FGFR4-induced signature was an independent prognostic factor beyond subtype and stage. Supervised analysis of 77 primary tumors with paired metastases revealed that the FGFR4-induced signature was significantly higher in luminal/ER+ tumor metastases compared with their primaries. Finally, multivariate analysis demonstrated that the FGFR4-induced signature also predicted site-specific metastasis for lung, liver, and brain, but not for bone or lymph nodes. These data identify a link between FGFR4-regulated genes and metastasis, suggesting treatment options for FGFR4-positive patients, whose high expression is not caused by mutation or amplification." @default.
- W3037940748 created "2020-07-02" @default.
- W3037940748 creator A5009023956 @default.
- W3037940748 creator A5012974257 @default.
- W3037940748 creator A5014379154 @default.
- W3037940748 creator A5015289835 @default.
- W3037940748 creator A5020663699 @default.
- W3037940748 creator A5021488024 @default.
- W3037940748 creator A5025392552 @default.
- W3037940748 creator A5026463022 @default.
- W3037940748 creator A5029048001 @default.
- W3037940748 creator A5030362253 @default.
- W3037940748 creator A5033222993 @default.
- W3037940748 creator A5047612906 @default.
- W3037940748 creator A5052091829 @default.
- W3037940748 creator A5052268581 @default.
- W3037940748 creator A5053893264 @default.
- W3037940748 creator A5054811851 @default.
- W3037940748 creator A5054978528 @default.
- W3037940748 creator A5059201728 @default.
- W3037940748 creator A5059336129 @default.
- W3037940748 creator A5074104547 @default.
- W3037940748 creator A5075269446 @default.
- W3037940748 creator A5082695064 @default.
- W3037940748 creator A5084260063 @default.
- W3037940748 creator A5089513581 @default.
- W3037940748 creator A5091831331 @default.
- W3037940748 date "2020-08-17" @default.
- W3037940748 modified "2023-10-17" @default.
- W3037940748 title "FGFR4 regulates tumor subtype differentiation in luminal breast cancer and metastatic disease" @default.
- W3037940748 cites W1510884166 @default.
- W3037940748 cites W1518095394 @default.
- W3037940748 cites W1902958101 @default.
- W3037940748 cites W1908864745 @default.
- W3037940748 cites W1980207397 @default.
- W3037940748 cites W1982555128 @default.
- W3037940748 cites W1988476050 @default.
- W3037940748 cites W1992762981 @default.
- W3037940748 cites W1993450230 @default.
- W3037940748 cites W1994973292 @default.
- W3037940748 cites W1996958662 @default.
- W3037940748 cites W2000269004 @default.
- W3037940748 cites W2010457001 @default.
- W3037940748 cites W2011450474 @default.
- W3037940748 cites W2012416768 @default.
- W3037940748 cites W2026542427 @default.
- W3037940748 cites W2027239974 @default.
- W3037940748 cites W2033799985 @default.
- W3037940748 cites W2040914426 @default.
- W3037940748 cites W2053183259 @default.
- W3037940748 cites W2060866852 @default.
- W3037940748 cites W2067114310 @default.
- W3037940748 cites W2070294819 @default.
- W3037940748 cites W2074089196 @default.
- W3037940748 cites W2077673213 @default.
- W3037940748 cites W2078058991 @default.
- W3037940748 cites W2091841926 @default.
- W3037940748 cites W2096283457 @default.
- W3037940748 cites W2097255042 @default.
- W3037940748 cites W2098775844 @default.
- W3037940748 cites W2106292881 @default.
- W3037940748 cites W2106833357 @default.
- W3037940748 cites W2116760308 @default.
- W3037940748 cites W2119878357 @default.
- W3037940748 cites W2121518671 @default.
- W3037940748 cites W2124358769 @default.
- W3037940748 cites W2130410032 @default.
- W3037940748 cites W2130787560 @default.
- W3037940748 cites W2131994307 @default.
- W3037940748 cites W2132619562 @default.
- W3037940748 cites W2137162822 @default.
- W3037940748 cites W2141268830 @default.
- W3037940748 cites W2157145819 @default.
- W3037940748 cites W2157852151 @default.
- W3037940748 cites W2158357903 @default.
- W3037940748 cites W2164394286 @default.
- W3037940748 cites W2165575701 @default.
- W3037940748 cites W2165757793 @default.
- W3037940748 cites W2165818616 @default.
- W3037940748 cites W2167105148 @default.
- W3037940748 cites W2170866900 @default.
- W3037940748 cites W2182398260 @default.
- W3037940748 cites W2214074259 @default.
- W3037940748 cites W2271190552 @default.
- W3037940748 cites W2312003494 @default.
- W3037940748 cites W2314632338 @default.
- W3037940748 cites W2332292689 @default.
- W3037940748 cites W2336241137 @default.
- W3037940748 cites W2398235143 @default.
- W3037940748 cites W2399999257 @default.
- W3037940748 cites W2414214572 @default.
- W3037940748 cites W2469539903 @default.
- W3037940748 cites W2512271890 @default.
- W3037940748 cites W2531056238 @default.
- W3037940748 cites W2558715006 @default.
- W3037940748 cites W2560396529 @default.
- W3037940748 cites W2570752636 @default.
- W3037940748 cites W2591810315 @default.